Kornimate/medical-research-clean huggingface dataset:
a pilot program measuring effectiveness of health coaching interventions

Conditions: Sedentary Behavior; Nutritional and Metabolic Disease

Summary: women will participate in a workshop within a group and individual meetings. the workshop will include providing information regarding guidelines for healthy eating, engaging in physical activity, personal training tools to build self-efficacy and to encourage implementing a healthy life style.

participants are interviewed for eligibility and if appropriate sign consent and undergo measurements of weight, height and blood pressure. at the first meeting there is a pre-study questionnaires and initial coaching session eight group meetings will take place and will include: up-to-date knowledge on nutrition (by a dietitian), exercise (by a physiotherapist) and coping skills for stress (by a psychologist). additionally the meetings will also include coaching tools which the participants will practice during the session. the multidisciplinary team has been trained in coaching tools to evaluate in group settings. in the last meeting, participants will be asked to fill out post study questionnaires measurements will be taken (weight and blood pressure).

Eligibility criteria:
inclusion criteria: * over age 18 * women who agree to fill out questionnaires * women who agree to attend sessions (attending 80% of sessions) * women who are fluent in hebrew exclusion criteria: * pregnancy * women with significant untreated psychiatric diagnosis * insulin-dependent diabetes * end-stage renal disease * unstable angina * women who are not fluent in hebrew * women currently treated by multidisciplinary staff (eg, heart failure, cardio rehabilitation) * women who have been enrolled in other programs of the center at the discretion of the staff will not be included in the study * women who do not want to make a healthy lifestyle change * failure to reach 75% of sessions during the study.
ultrasound guided arthrocentesis

Conditions: Arthritis; Joint Pain

Summary: does ultrasound guidance improve success rate and decrease aspiration attempts for peripheral arthrocentesis?


Eligibility criteria:
inclusion criteria: * age at or over 18 * indication for peripheral arthrocentesis exclusion criteria: * hemodynamic instability * previous arthroplasty of the joint * known intraarticular fracture * hip arthrocentesis

Keywords: arthrocentesis ultrasound emergency
the safety and efficacy of alpha-1 antitrypsin (aat) for the prevention of graft-versus-host disease (gvhd) in patients receiving hematopoietic cell transplant

Conditions: Acute-graft-versus-host Disease

Summary: this study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute gvhd (agvhd) in participants undergoing an unrelated (matched or single allele mismatched) or matched related allogeneic hematopoietic cell transplantation (hct).


Eligibility criteria:
inclusion criteria: * male or female participants, \>=12 years of age (\>= 18 years of age for participants at german sites only), undergoing hct for hematological malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms. * planned myeloablative conditioning regimen. * participants must have a related or unrelated donor as follows: * related donor must be a 6 / 6 match for human leukocyte antigen (hla)-a, -b, at intermediate (or higher) resolution, and -dr beta 1 (drb1) at high resolution using deoxyribonucleic acid (dna)-based typing. * unrelated donor must be 7 / 8 or 8 / 8 match for hla-a, -b, and -c at intermediate (or higher) resolution, and -drb1 at high resolution using dna-based typing. exclusion criteria: * prior autologous or allogeneic hct. * t cell depleted transplant or planned use of anti-t cell antibody therapy either ex vivo or in vivo (ie, anti thymocyte globulin \[atg\], alemtuzumab) for gvhd prophylaxis. * planned umbilical cord blood transplant. * planned use of cyclophosphamide after hct for gvhd prophylaxis. * planned haploidentical donor.
the effect of an antibiotic on the production of uremic toxins by the gut microbiome

Conditions: End Stage Renal Disease

Summary: the purpose of this study is to determine if multiple doses of vancomycin over the course of 3 months will perturb the intestinal flora (microbiome) and result in reduced serum concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. the design of the study will permit investigators to assess the variability of serum uremic retention solute concentrations with and without antibiotic over a three-month period.


Eligibility criteria:
inclusion criteria: * patients with stable chronic kidney disease on hemodialysis with a fistula or an av graft. exclusion criteria: * antibiotics received within the last 3 months; * recent diarrhea * known allergy to vancomycin * history of c. difficile infection * elevation of white blood cell count or fever within one week of enrollment.
evaluation of the organization of continuity of care for home hospice patients by four parisian health networks

Conditions: Neoplasms; Neurodegenerative Diseases; Terminal Illness

Summary: in paris, france, home hospice care for terminally ill patients is organized by four "palliative care networks". these networks are responsible for information sharing and coordination of all health care professionals working with the patient. two different systems are in place to ensure continuity of care outside working hours, in such a setting. in the first system, palliative care specialists from the network are reachable over the phone 24/7 by the patient or its caregivers, whenever needed. in the second system, medical information about the patient, regularly updated by the network's medical team, is available to professionals via a secure website, so that in case the patient requires an urgent medical home visit outside working hours, the visiting physician has access to accurate information. the study's goal is to compare patient's and caregiver's satisfaction between these two systems of continuity of care. for that purpose, patients will be taken care of as usual by every palliative care network. in every instance where the patient or caregivers have reached out for medical help through the network's continuity of care system, the patient or caregiver will be called 5 days later by the investigation team to go through a satisfaction questionnaire (likert scales)


Eligibility criteria:
inclusion criteria: * patient has a disease with fatal prognosis and requires palliative care * patient lives in paris, france * patient benefits from home hospice care through one of the four official paris palliative care networks exclusion criteria: * pregnant women * breastfeeding womed * altered cognitive function with a mini mental status below 20 * patient not able to communicate or not speaking french * patient legally not capable of giving informed consent
cognitive impairment in patients with heart failure

Conditions: Heart Failure; Cognitive Impairment

Summary: the aim of the present study is threefold: investigating 1) specific cognitive impairments in patients with congestive heart failure, 2) whether cognitive impairments in patients with decompensated heart failure improve after medical recompensation and 3) whether cognitive functioning is related to the long-term prognosis (mortality, rehospitalisation) of those patients.

the daily routine in clinical settings often shows cognitive impairments in patients with congestive heart failure. recent studies reported declines in cognitive functioning such as executive functions, episodic memory, perceptual speed and attention. however, less is known regarding the differential impairments of cognitive functioning in patients with decompensated heart failure. study objectives: 1. identifying specific cognitive impairments in patients with congestive heart failure compared to healthy controls 2. evaluating the influence of acute decompensation in congestive heart failure on cognitive functioning 3. investigating the effects of medical treatment on cognitive functioning in patients with decompensated heart failure 4. exploring long-term effects of cognitive and physiological status on hospitalisation and/or mortality study design: cognitive functions of patients with decompensated heart (nyha iii-iv) failure are compared to age and gender matched patients with congestive heart failure (nyha iii-iv) without symptoms of cardiac decompensation and with healthy controls. decompensated patients are tested before and after medical recompensation. for matched patients and controls, the pretest-posttest timing is based on the recompensation time of the respective patient with decompensated heart failure. the neuropsychological test battery includes measures of episodic memory, working memory, short-term memory, executive functions, perceptual speed and intelligence. in addition, the study applied standardized questionnaires of self assessed quality of life and depression. relevant physiological data, such as left ventricular systolic function and n-terminal pro brain natriuretic peptide (nt-pro-bnp), are recorded.

Eligibility criteria:
criteria of decompensated heart failure patients inclusion criteria: * decompensated heart failure patients * nyha iii-iv * ejection fraction \< 35% exclusion criteria: * psychosis * dementia * major depression * reanimation (\<3month) * patients with assist device system

Keywords: cognition decompensation heart failure recompensation
weekly use of teriparatide to accelerate healing of distal radius fracture

Conditions: Colles' Fracture

Summary: the purpose of this study is to examine the effect of weekly dosing strategy on fracture healing.


Eligibility criteria:
inclusion criteria: 1. postmenopausal women aged 45-75 (at least 2 years after menopause) 2. with primary osteoporosis 3. patients with colles fractures with a fracture time of no more than 7 days 4. conservative treatment after fracture (closed reduction and immobilization) 5. no multiple fractures 6. informed well and agree to participate in this clinical trial exclusion criteria: 1. combine other physical diseases, including diabetes, severe hypertension, autoimmune diseases, heart, liver and kidney diseases, malignant tumors, mental illnesses, and other diseases that doctors believe may affect the healing process. 2. in addition to primary osteoporosis, any disease affecting bone metabolism or treatment response, including serum pth\>65pg/ml, 25-hydroxyvitamin d\ 135u/l, history of bone tumor, paget disease, history of radiotherapy 3. the fracture site has a history of trauma or surgery, affecting the function of the wrist or forearm 4. those who are allergic to pth or any excipients 5. currently receiving anti-osteoporosis treatment or receiving other anti-osteoporosis treatment during the trial 6. contraindication of teriparatide including hyperparathyroidism, severe renal insufficiency, hypercalcemia, etc.
impact of dental desensitization facilitated by a child life specialist distress and cooperation

Conditions: Desensitization; Dental Anxiety; Dental Care; Distress, Emotional; Cooperation, Patient

Summary: the aim of this study is to evaluate whether dental desensitization visits facilitated by a certified child life specialist (ccls) significantly impact pediatric patients' distress and cooperation levels from the start of desensitization visit(s) to end of the desensitization visit(s), end of desensitization visit to start of subsequent hygiene appointment, and end of hygiene appointment.


Eligibility criteria:
inclusion criteria: * patients and parents of patients aged 2-25 years who have been referred to the desensitization clinic. * patients who meet with a ccls for dental desensitization. exclusion criteria: * patients younger than 2 years old and older than 25 years old.
chemotherapy plus cetuximab followed by surgical resection in patients with locally advanced or recurrent thymoma or thymic carcinoma

Conditions: Thymoma; Thymic Carcinoma; Clinical Masaoka Stage II to IVA

Summary: the main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thymoma or thymic carcinoma before surgery. the physicians will also look at changes in genes in the tumor that may relate to the effectiveness of cetuximab


Eligibility criteria:
inclusion criteria: * age\>18 * karnofsky performance status (kps) ≥ 70 * newly diagnosed or recurrent thymoma - who a, ab, b1, b2, or b340, or thymic carcinoma pathologically confirmed at mskcc, mdacc or city of hope * no prior chemotherapy, radiotherapy, or surgical therapy (other than for diagnostic biopsy) for thymoma * no prior treatment with cetuximab * clinical masaoka stage ii (\>5cm), iii, or iva(see appendix b), including suspected invasion of mediastinum, pericardium, lung, great vessels or chest wall, and/or pleural metastases normal marrow function: leukocytes ≥ 4,000/μl, absolute neutrophil count ≥ 1,500/μl, platelets ≥ 160,000/μl * adequate renal function, with creatinine ≤ 1.3 mg/dl or calculated creatinine clearance ≥60ml/min by cockcroft and gault equation using parameters of age, weight (kg), and baseline serum creatinine (mg/dl) * adequate hepatic function: total bilirubin ≤1.5 mg/dl, ast ≤1.5x unl, alkaline phosphatase ≤1.5 un * signed informed consent * effective contraception * medically operable exclusion criteria: * evidence of distant metastatic disease (masaoka stage ivb) * thymic carcinoid * patients must not be receiving any other investigational agents * concurrent or prior malignancy in the last 5 years other than non-melanoma skin cancer and in-situ carcinoma of the cervix * known hiv-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with the study drugs. patients on medications known to alter cyp3a4 * pregnant or breastfeeding women

Keywords: cetuximab cisplatin cyclophosphamide 09-038
diagnosis of pulmonary embolism by doppler signals

Conditions: Pulmonary Embolism

Summary: the lds may contain information of significant diagnostic and physiological value regarding the pulmonary parenchyma and vasculature, as well as the cardio- vascular system in general. in pilot clinical studies of patients with acute decompensated heart failure (adhf) as well as patients with pulmonary hypertension, lds signals patterns unique to these conditions were identified. we believe that these newly discovered ultrasound signals might provide a non-invasive radiation-free means to diagnose and monitor patients with pulmonary embolism. the purpose of this study is to assess the utility of noninvasive assessment of lung doppler signals performed via transthoracic parametric doppler. the objective of the study is to evaluate the lung doppler signals (lds) in patients diagnosed with acute pe, in order to determine the potential assessment value of this non-invasive method in this potentially life threatening condition.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of acute pe on cta exclusion criteria: * pregnant women * inability to consent * patients with severe chest wall deformity * previously diagnosed pe * pneumonia * pulmonary edema * pneumothorax * severe copd (gold class iii, iv) * hemodynamically unstable patients

Keywords: pulmonary embolism pulmonary disease lung doppler signals
a clinical trial comparing the efficacy and safety of 2 different initial dose prescriptions for exubera.

Conditions: Diabetes Mellitus, Type 2

Summary: the primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (exubera) achieves glycemic control (hba1c) after 16 weeks that is non-inferior compared to the standard weight-based formula.


Eligibility criteria:
inclusion criteria: * diabetes mellitus type 2 * currently treated with at least 2 oral anti-diabetic agents exclusion criteria: * severe asthma, severe copd * smoking
study of 3d radiotherapy with or without erlotinib (tarceva®) in patients with localized non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: a phase ii, multicenter, randomized trial of 3d radiotherapy versus 3d radiotherapy and erlotinib (tarceva®) in patients with localized-unresectable (ia-iiib) non-small cell lung cancer non susceptible for chemotherapy treatment, to compare safety and toxicity profile, and the progression-free survival in both arms of treatment (3d radiotherapy versus 3d radiotherapy + erlotinib) in patients who have not received previous chemotherapy.


Eligibility criteria:
inclusion criteria: * written informed consent prior to any specific procedure of the protocol. * histologically confirmed diagnosis of non small cell lung cancer. * unresectable (ia-iiib) non-small cell lung cancer. * patients non susceptible for chemotherapy treatment * measurable disease according to recist criteria * age \> 18 years. * ecog performance status \< 2. * adequate bone marrow, hepatic, renal and respiratory function. * patients capable of following an adequate therapeutic compliance and accessible for a correct follow-up. * women at a fertile age must have a negative serum or urine pregnancy test within the 7 days prior to the beginning of the treatment. * patients of both genders at a fertile age, including those women having their last menstruation within the two previous years, must follow effective contraceptive measures. exclusion criteria: * prior chemotherapy or radiotherapy. * history of other curatively treated malignancy and no evidence of disease within the past 5 years except squamous cell skin cancer, or resected cervix carcinoma. * pregnant or lactating women. * any other severe disease or clinical conditions, as, but not only: 1. unstable cardiopathy despite treatment, myocardial infarction within the 6 months before entering the study 2. uncontrolled active infection 3. uncontrolled peptic ulcer, unstable diabetes mellitus or any other contraindication for treatment with corticosteroids. 4. autoimmune diseases. * concomitant treatment with any other antineoplastic therapy. * prior experimental pharmacological agent within the 3 weeks prior to the inclusion of the study. * prior treatment with egfr targeted therapies. * erlotinib known hypersensibility. * any radiotherapy treatment contraindication. * history of significant neurological or psychiatric disorders, including epileptic seizures. * any significant ophthalmologic impairment of the eye surface (use of contact lenses is not recommended) * inability to take oral medication and surgical procedures affecting the absorption or implying intravenous or parenteral feeding. * any other underlying severe process affecting the ability to take part in the study.

Keywords: nsclc, lung cancer patients with localized-unresectable (ia-iiib) non-small cell lung cancer non susceptible for chemotherapy treatment.
expiratory muscle strength training in improving bulbar function and quality of life in patients with head and neck cancer

Conditions: Malignant Head and Neck Neoplasm

Summary: this randomized clinical trial studies how well expiratory muscle strength training works in improving bulbar function and quality of life in patients with head and neck cancer. expiratory muscle strength training may help to strengthen the muscles involved in breathing and swallowing and may allow improved breathing, airway safety, swallow function, and quality of life in patients with head and neck cancer.

primary objectives: i. investigate the impact of a prophylactic targeted exercise program, expiratory muscle strength training (emst), on swallowing function and well-being of individuals on head and neck cancer (hnc). ii. determine the impact of emst on objective respiratory measures of individuals with hnc. iii. determine the relationship between mean dose across the swallowing muscles (oral tongue and supra-hyoids, base of tongue, superior, middle and inferior pharyngeal constrictors, proximal esophagus)/dose on each muscle and the swallowing functional outcomes from aim 1. outline: patients are randomized to 1 of 2 arms. arm i: patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions. arm ii: patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. patients also participate in an emst session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy. after completion of study, patients are followed up at 1, 3, 6, and 12 months.

Eligibility criteria:
inclusion criteria: * patients with a definitive, curative treatment plan consisting of chemoradiation for head \& neck cancer * surgery, if required, must be limited to: diagnostic biopsy exclusion criteria: * participants enrolled in a radiation de-intensification protocol * current or previous neurological disease, which may adversely affect swallowing * history of oropharyngeal swallowing disorder prior to cancer diagnosis * previous neurosurgery on the brain * severe chronic obstructive pulmonary disease (copd) requiring oxygen dependence, as this is a contraindication of emst
follow-up study of patients previously treated with pimecrolimus tablets for chronic plaque-type psoriasis

Conditions: Psoriasis

Summary: this extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.


Eligibility criteria:
inclusion criteria: * consenting patients who participated in the core clinical trial

Keywords: safety, psoriasis, adverse event, sae, extension
cardiovascular safety research: bupivacaine with vasoconstrictor versus ropivacaine in brachial plexus block

Conditions: Injuries, Hand; Anesthesia Conduction; Anesthetics, Local

Summary: the purpose of this study is to determine if bupivacaine (75% levobupivacaine plus 25% racemic bupivacaine) with vasoconstrictor is effective and safety as ropivacaine in brachial plexus block for orthopedic surgery.

the intoxication by bupivacaine is considered life threatening. currently the most safety local anesthetic in substitution to bupivacaine is ropivacaine, however in brasil there is a bupivacaine mixture of 75% levobupivacaine plus 25% racemic bupivacaine. the research design is: patients involved: 48; age: 18 to 40 years old; both sex; asa i and ii. surgery: elective upper extremity orthopedic surgery. anesthesia technique: brachial plexus block. primary endpoint: cardiovascular safety; analysis by continuous holter. secondary endpoint: anesthetic and analgesic efficacy.

Eligibility criteria:
inclusion criteria: * patients involved: 48; asa i and ii; * surgery: elective upper extremity orthopedic surgery. exclusion criteria: * contraindications to anesthesia technique and/or to local anesthetic; * participation in different trials in the last two months; * antiretroviral users; * obesity.

Keywords: ropivacaine bupivacaine upper extremity local anesthetic